Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 53

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 53
---
 ​ | Achievementof Target (%) |   |    |   | ​ |
| Rick Winningham  | ​ | ​ | Chief Executive Officer                            | ​ | ​ | ​              | ​ | 500,000 | ​ | ​ | ​ | ​                        | ​ | 80 | ​ | ​ |
| Aziz Sawaf       | ​ | ​ | Senior Vice President, Chief Financial Officer     | ​ | ​ | ​              | ​ | 197,000 | ​ | ​ | ​ | ​                        | ​ | 85 | ​ | ​ |
| Brett A. Grimaud | ​ | ​ | Senior Vice President, General Counsel & Secretary | ​ | ​ | ​              | ​ | 205,000 | ​ | ​ | ​ | ​                        | ​ | 85 | ​ | ​ |

2024 Equity Compensation Our long-term equity incentives seek to support our strategy of attracting employees with excellence and expertise in a wide variety of functional areas (e.g., clinical science, clinical trial execution, partnering and collaboration, strategic marketing, marketing science and financial planning). Equally as important, our equity incentives seek to support a culture that emphasizes teamwork as well as long-term retention of our employees in an intensely competitive environment. Options have been used primarily as a hiring incentive, with annual replenishment awards historically provided primarily in the form of RSUs to minimize dilution to shareholders. Annual replenishment equity awards generally are considered during the first quarter of each year, and additional equity awards may be made in certain other circumstances throughout the year. Replenishment equity awards generally vest over a four-year period. We believe that the resulting overlapping vesting schedule from awards made in prior years, together with the number of shares subject to each award, helps ensure a meaningful incentive to remain in our employ and to enhance shareholder value over time.

34

TABLE OF CONTENTS

During 2024, all of our named executive officers were awarded both RSUs and PSUs pursuant to our 2013 Equity Incentive Plan. The RSUs awarded to our named executive officers in 2024 vest over four years, with 25% vesting on February 20, 2025, and the remaining RSUs vesting in equal quarterly installments on the Company vesting dates for the three years thereafter, provided that the named executive officer remains in continuous service through each such date. The PSUs awarded to our named executive officers are eligible to vest subject to the achievement of three share price appreciation milestones set forth below within four years of the date